Evidence map›Paper›PMID 42250325›Full record

ArticleEBioMedicine2026

Refined single-cell profiling captures a CCR5

Fabiënne van Puijfelik, Jasper Rip, Yifan van Hasselt, Annet F Wierenga-Wolf, Sophie Shyfrin, Anna C Pelser, Marie-Jose Melief, Romy A M Klein Kranenbarg, Eric M Bindels, Harmen J G van de Werken and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fabiënne van PuijfelikDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Jasper RipDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Yifan van HasseltDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Annet F Wierenga-WolfDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Sophie ShyfrinDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Anna C PelserDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Marie-Jose MeliefDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Romy A M Klein KranenbargMS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Eric M BindelsDepartment of Hematology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Harmen J G van de WerkenDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Chaja M J van AnsenwoudeDepartment of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam Institute for Infection and Immunity, Amsterdam UMC Location Vrije Universiteit, Amsterdam, the Netherlands; MS Center Amsterdam, Amsterdam UMC Location Vrije Universiteit, Amsterdam, the Netherlands.
Helga E de VriesDepartment of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam Institute for Infection and Immunity, Amsterdam UMC Location Vrije Universiteit, Amsterdam, the Netherlands; MS Center Amsterdam, Amsterdam UMC Location Vrije Universiteit, Amsterdam, the Netherlands.
Willem A DikDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Laboratory Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Janet de BeukelaarDepartment of Neurology, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
Ide SmetsMS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Beatrijs H WokkeMS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Joost SmoldersDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; Neuroimmunology Research Group, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands.
Marvin M van LuijnDepartment of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands; MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address: m.vanluijn@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDecades of immunological and genetic studies highlight CD4

methodsFeatures that distinguished Th17.1 from Th17 and Th1 cells in the blood were explored using spectral flow cytometry. We focused on the brain-homing properties of Th17.1 in MS by analysing paired blood and cerebrospinal fluid (CSF) as well as blood before and after natalizumab treatment. Identified Th17.1 effector signatures were further analysed using purified subsets for single-cell transcriptomics and corresponding in vitro stimulation assays.

findingsOur screens reveal an CCR5

interpretationWe show that low-frequency, circulating Th17.1 cells harbour a unique MS-associated CCR5

fundingZonMw (09150171910036), Stichting MS Research (19-1075 MS, 23-490 g MS), European Union's Horizon Europe Research and Innovation Actions (101137235; BEHIND-MS) and the Swiss State Secretariat for Education, Research and Innovation (SERI), Erasmus MC Foundation (10502/02).

Indexed as

CD4-Positive T-LymphocytesMultiple SclerosisReceptors, CCR5Single-Cell AnalysisT-Lymphocytes, CytotoxicAdultBiomarkersFemaleGene Expression ProfilingHumansImmunophenotypingMaleNatalizumabTh17 CellsTranscriptomeBiomarkersCCR5 protein, humanNatalizumabReceptors, CCR5CCR5CD4(+) T cellCytotoxic T lymphocytes (CTL)Multiple sclerosis (MS)Single-cell RNA sequencing (scRNA-seq)Th17.1 cells

Identifiers

PMID42250325
PMCPMC13264205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.